MYCN and glioblastoma: Aberrant activity of N-MYC has been reported in numerous other cancer types, including neuroblastoma, neuroendocrine prostate cancer, breast cancer, glioblastoma multiforme, and small cell lung cancer (21), where N-MYC has been implicated in driving tumorigenesis, leading to poor prognosis.